The ability of IL-15 DCs to specifically harness the CD56bright NK cell compartment may be of particular relevance for immunotherapy since CD56bright NK cells have been identified as the predominant tumor-infiltrating NK cell population [8,67]. The gene discussed is IL15; the disease is neoplasm.